Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling via Inhibiting GSDMD-Mediated Inflammation

Figure 4

Oridonin attenuated myocardial cardiac remodeling by inhibiting GSDMD-mediated inflammation in vivo. The mice were examined with an echocardiogram at the end of the animal experiment. (a) Representative cardiac echocardiographic images of the four groups of mice. (b, c) EF and FS values for the four groups. (d) Changes in blood pressure in mice of each group during modeling. (e, f) Hypertrophy and fibrosis levels in cardiac tissue were detected by western blotting. (g) Representative H&E and Sirius red staining of each group also showed disordered myocardial cell structure and fibrosis in cardiac tissue. (g–i) The results of IHC showed the different expression levels of GSDMD in cardiac tissue corresponding to the results of western blot. (j) The content of IL-1β in serum. (k) The relevant semiquantitative statistical graph of GSDMD-IHC. (l, m) Gel images of NLRP3, IL-1β, and IL-18 in myocardial tissue and its semiquantitative statistical graph. compared with control; ^# compared with Ang II. EF: ejection fraction; FS: fractional shortening.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)